Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

52 results
Display

Euglycemic Diabetic Ketoacidosis When Reducing Insulin Dosage in Patients Taking Sodium Glucose Cotransporter 2 Inhibitor

Yi WJ, Kim SK, Youn SU, Kang N, Lee MW, Park SO

Sodium glucose cotransporter 2 (SGLT2) inhibitor has been recently reported of diabetic ketoacidosis due to accumulation of ketone bodies in patients with severe dehydration caused from such like diarrhea even...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Diabetic Ketoacidosis Induced by Sodium-Glucose Cotransporter 2 Inhibitor

Jun JH, Choe KJ, Woo YM, Park YR, Park YK, Kim WJ, Shim MS, Kim JY

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral antihyperglycemic drugs; inhibition of the cotransporter allows for increased renal glucose excretion that consequently leads to reduced plasma glucose...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sodium-Glucose Cotransporter-2 Inhibitor-Metformin Therapy in South Asians: From Guideline Adoption to Context-Specific Safety Gaps

Nizam R, Devi C, Shafqat R, Shuja M

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Case of hyperosmolar hyperglycemic state by a sodium-glucose cotransporter 2 inhibitor

Nho IY, Kim HS, Kang NK, Lee MW, Kim SK, Park SO

Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) are proposed as a novel approach for the management of type 2 diabetes mellitus. SGLT2 cotransporters are responsible for reabsorption of 90 %...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sodium-Glucose Cotransporter 2 Inhibitors for People with Type 1 Diabetes

Kim CH, Moon JS

Althowgh intensive insulin regimen is the main treatment in people with type 1 diabetes, glucose variability and weight gain remain as challenges for this treatment. Sodium-glucose cotransporter (SGLT) inhibitors (including...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice

Kim NH, Kim SG

Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose co-transporter 2 (SGLT2) inhibitors are newer classes of glucose-lowering agents that are currently widely used in clinical practice. Their glycemic efficacy and cardiovascular...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitor and Its Possible Cardioprotective Mechanism

Cho Y, Kang ES

Patients with type 2 diabetes (T2D) have a significantly higher risk of developing cardiovascular diseases such as myocardial infarction, heart failure, and stroke. Current anti-diabetic drugs are highly effective for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

Jung CH, Mok JO

The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor

Hwang YC, Kim JH, Lee BW, Lee WJ

We aimed to identify the clinical variables associated with a better glucose-lowering response to the sodium glucose cotransporter 2 inhibitor ipragliflozin in people with type 2 diabetes mellitus (T2DM). We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Euglycemic diabetic ketoacidosis development in a patient with type 2 diabetes receiving a sodium-glucose cotransporter-2 inhibitor and a carbohydrate-restricted diet

Koh G, Bang J, Yoo S, Lee SA

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become increasingly prescribed because of their proven protective effects on the heart and kidneys, and carbohydrate-restricted diets are popular therapeutic approaches for patients with obesity...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)

Kawada T

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats

Lee KA, Jin HY, Lee NY, Kim YJ, Park TS

The effect of sodium-glucose cotransporter 2 inhibitors on peripheral nerves and kidneys in diabetes mellitus (DM) remains unexplored. Therefore, this study aimed to explore the effect of empagliflozin in diabetic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Metabolic Impact of Sodium-Glucose Cotransporter 2 Inhibitor-Induced Ketogenesis in Type 2 Diabetes Mellitus

Park HW, Choe HJ, Lim HJ, Kong SH, Oh TJ, Kim MJ, Moon JH, Choi SH, Lim S, Moon JH

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycemic control and confer cardiovascular and renal benefits in individuals with type 2 diabetes mellitus (T2DM) partly by promoting urinary glucose excretion and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Preventive Effect of an SGLT2 Inhibitor on Cardiovascular Disease in an Observational Study: Results from a Korean Population

Ha KH, Kim DJ

The sodium-glucose cotransporter-2 inhibitor (SGLT2i) is a new anti-hyperglycemic agent that have function to concomitantly inhibit the reabsorption of glucose and sodium in the renal proximal convoluting tubule. Recent two...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?

Seo JA

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study

Kim HS, Yoon T, Jung CH, Park JY, Lee WJ

Sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) are novel anti-diabetic drugs whose glucose-lowering effect and cardiovascular and renal benefits were evidenced in clinical trials. We investigated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Fournier’s Gangrene in an HIV-Positive Patient Using a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report

Yoon W, Lee JH

Fournier’s gangrene (FG) is a rapidly progressive necrotizing fasciitis affecting the perineal, genital, or perianal regions. It is a rare but potentially life-threatening condition that predominantly affects immunocompromised individuals, including...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights

Baek HS, Jeong C, Yang Y, Lee J, Lee J, Lee SH, Cho JH, Sohn TS, Son HS, Yoon KH, Lee EY

One of the notable adverse effects of sodium-glucose cotransporter 2 (SGLT2) inhibitor is diabetic ketoacidosis (DKA) often characterized by euglycemia. In this retrospective review of patients with DKA from 2015...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Long-term Sodium-glucose Cotransporter 2 Inhibitor Treatment on Renal Function in the Patients with Type 2 Diabetes

Baek JH, Oh TJ, Moon JY, Kim T, Ko SH, Moon MK, Kim HJ, Lee DW, Hur KY

Chronic kidney disease is developed commonly in type 2 diabetes mellitus (T2DM) and is the most common cause of end-stage renal disease and related cardiovascular complications. Meanwhile, despite the current...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of SGLT2 inhibitor/metformin fixed dose combination in Korea

Choi HE, Lee JW, Je NK, Jeong KH

Background: The use of combination therapy and fixed-dose combination therapy is increasing for the treatment of type 2 diabetes. Sodium glucose cotransporter-2 inhibitor (SGLT2i) is a drug class used in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2026 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr